Immunogenicity of Therapeutic Proteins: A Regulatory Perspective

Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations

Volumn , Issue , 2011, Pages 13-35

  Kirshner, Susan ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antitherapeutic immune response, and clinical management dependence on factors; Life threatening immune responses ATAs cross reacting, neutralizing endogenous proteins; Regulatory requirements, therapeutic protein immunogenicity a regulatory perspective

Indexed keywords

EID: 84886030311     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118075685.ch2     Document Type: Chapter

References (85)

1. Koren, E., Smith, H.W., Shores, E., Shankar, G., Finco-Kent, D., Rup, B., Barrett, Y.C., Devanarayan, V., Gorovits, B., Gupta, S., Parish, T., Quarmby, V., Moxness, M., Swanson, S.J., Taniguchi, G., Zuckerman, L.A., Stebbins, C.C., Mire-Sluis, A. ( 2008 ). Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products . J Immunol Methods, 333, 1-9 .
2. US Government . 2009 . Code of Federal Regulations . Title 21, Food and Drugs.
3. Mire-Sluis, A.R., Barrett, Y.C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., Swanson, S.J., Taniguchi, G., Wierda, D., Zuckerman, L.A. ( 2004 ). Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products . J Immunol Methods, 289, 1-16 .
4. Shankar, G., Devanarayan, V., Amaravadi, L., Barrett, Y.C., Bowsher, R., Finco-Kent, D., Fiscella, M., Gorovits, B., Kirshner, S., Moxness, M., Parish, T., Quarmby, V., Smith, H., Smith, W., Zuckerman, L.A., Koren, E. ( 2008 ). Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products . J Pharm Biomed Anal, 48, 1267-1281 .
5. Gupta, A., Indelicato, S.R., Jethwa, V., Kawabata, T., Kelley, M., Mire-Sluis, A.R., Richards, S.M., Rup, B., Shores, E., Swanson, S.J., Wakshull, E. ( 2007 ). Recommendations for the design, optimization and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics . J Immunol Methods, 321, 1-18 .
6. Food and Drug Administration (FDA) . ( 2009 ). Draft guidance for industry: assay development for immunogenicity testing of therapeutic proteins . CEDER. December 2009.
7. Rosenberg, A.S. ( 2003 ). Immunogenicity of biological therapeutics: a hierarchy of concerns . Dev Biol Basal, 112, 15-21 .
8. Schernthaner, G. ( 1993 ). Immunogenicity and allergenic potential of animal and human insulins . Diabetes Care, 16 ( Suppl. 3 ), 155-165 .
9. Foss, F.M., Bacha, P., Osann, K.E., Demierre, M.V., Bell, T., Kuzel, T. ( 2001 ). Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication . Clin Lymphoma, 1 ( 4 ), 298-302 .
10. Rosenberg, M., Kingma, W., Fitzpatrick, M.A., Richards, S.M. ( 1999 ). Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration . Blood, 93, 2081-2088 .
11. Sharma, B. ( 2007 ). Immunogenicity of therapeutic proteins. Part 1. Impact of product handling . Biotech Adv, 25, 310-317 .
12. Fotiou, F., Aravind, S., Wang, P-P., Nerapusee, O. ( 2009 ). Impact of illegal trade on the quality of epoetin alfa in Thailand . Clin Ther, 31 ( 2 ), 336-346 .
13. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., Kuter, D.J. ( 2001 ). Thrombocytopenia caused by the development of antibodies to thrombopoietin . Blood, 98, 3241-3248 .
14. Basser, R., O ' Flaherty, E., Green, M., Edmonds, M., Nichol, J., Menchaca, D., Cohen . B., Begley, C. . ( 2002 ). Development of pancytopaenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor . Blood, 99, 2599-2602 .
15. Kuter, D.J. ( 2009 ). Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia . Annu Rev Med, 60, 193-206 .
16. Ponce, E., Moskovitz, J., Grabowski, G. ( 1997 ). Enzyme therapy in Gaucher disease type I: effect of neutralizing antibodies to acid-glucosidase . Blood, 90, 43-48 .
17. Brooks, D.A., Kakavanos, R., Hopwood, J.J. ( 2003 ). Significance of immune response to enzyme-replacement therapy for patients with lysosomal storage disorder . Trends Mol Med, 9 ( 10 ), 450-453 .
18. Brackmann, H.H., Lenk, H., Scharrer, I., Auerswald, G., Kreuz, W. ( 1999 ). German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies . Haemophilia, 5, 203-206 .
19. Hay, C.R., Baglin, T.P., Collins, P.W., Hill, F.G., Keeling, D.M. ( 2000 ). The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors ' Organization (UKHCDO) . Br J Haematol, 111, 78-90 .
20. Calabresi, P.A., Giovannoni, G., Confavreux, C., Galetta, S.L., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H., O ' Connor, P.W., Phillips, J.T., Polman, C.H., Radue, E.W., Rudick, R.A., Stuart, W.H., Lublin, F.D., Wajgt, A., Weinstock-Guttman, D.R., Lyn, F., Panzara, M.A. ( 2007 ). The incidence and significance of anti-natalizumab antibodies . Neurology, 69, 1391-1403 .
21. Pringle, P.H., Hindmarsh, P.C., Di Silvio, L., Teale, J.D., Kurtz, A.B., Brook, C.G. ( 1989 ). The measurement and effect of growth hormone in the presence of growth hormone-binding antibodies . J Endocrinol. 121 ( 1 ), 193-199 .
22. Chen, E., Zhao, M., Mundy, G.R. ( 2004 ). Bone morphogenic proteins . Growth Factors, 22 ( 4 ), 233-241 .
23. Rosen, V. ( 2009 ). BMP2 signaling in bone development and repair . Cytokine Growth Factor Rev, 20, 475-480 .
24. Schwartz, R. ( 1999 ). Immunological tolerance . In Fundamental Immunology, 4th edition. Paul WE, ed. Lippencott- Raven Publishers, Philadelphia.
25. Rosenberg, A.S. ( 2006 ). Effects of protein aggregates: an immunologic perspective . AAPS J, 8 ( 3 ), E501-E507 .
26. Filipe, V., Hawe, A., Schellekens, H., Jiskoot, W. ( 2010 ). Aggregation and immunogenicity of therapeutic proteins . In Aggregation of Therapeutic Proteins . Wang W, Roberts CJ, eds. John Wiley and Sons, Hoboken, NJ .
27. Moore, W.V., Leppert, P. ( 1980 ). Role of aggregated human growth hormone (hGH) in development of antibodies to hGH . J Clin Endocrinol Metab, 51 ( 4 ), 691-697 .
28. Barandun, S., Kistler, P., Jeunet, F., Isliker, H. ( 1962 ). Intravenous administration of human ?-globulin . Vox Sang, 7, 157-174 .
29. Ellis, E.F., Henney, C.S. ( 1969 ). Adverse reactions following administration of human gamma globulin . J Allergy, 43 ( 1 ), 45-54 .
30. Gamble, C.N. ( 1966 ). The role of soluble aggregates in the primary immune response of mice to human gamma globulin . Int Arch Allergy Appl Immunol, 30 ( 5 ), 446-55 .
31. Wang, W., Nema, S., Teagarden, D. ( 2010 ). Protein aggregation - pathways and influencing factors . Int J Pharm, 390, 89-99 .
32. Bryson, C.J., Jones, T.D., Baker, M.P. ( 2010 ). Prediction of immunogenicity of therapeutic proteins: validity of computational tools . Biodrugs, 24 ( 1 ), 1-8 .
33. Koren, E., De Groot, A.S., Jawa, V., Beck, K.D., Boone, T., Rivera, D., Li, L., Mytych, D., Koscec, M., Weeraratne, D., Swanson, S., Martin, W. ( 2007 ). Clinical validation of the " in silico " prediction of immunogenicity of a human recombinant therapeutic protein . Clin Immunol, 124, 26-32 .
34. De Groot, A.S., Scott, D.W. ( 2007 ). Immunogenicity of protein therapeutics . Trends Immunol, 28 ( 11 ), 482-490 .
35. Brand, C.M., Leadbeater, L., Bellati, G., Marotta, F., Ideo, G. ( 1993 ). Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-a subtypes . J Interferon Res, 13, 121-125 .
36. Werdelin, O., Meldal, M., Jensen, T. ( 2002 ). Processing of glycans on glycoprotein and glycopeptide antigens in antigen presenting cells . PNAS, 99 ( 15 ), 9611-9613 .
37. Green, R.S., Stone, E.L., Tenno, M., Lehtonen, E., Farquhar, M.G., Marth, J.D. ( 2007 ). Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis . Immunity, 27, 308-320 .
38. Gribben, J.G., Devereux, S., Thomas, N.S., et al. ( 1990 ). Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF . Lancet, 335, 434-437 .
39. Dzhambazov, B., Holmdahl, M., Yamada, H., Lu, S., Vestberg, M., Holm, B., Johnell, O., Kihlberg, J., Holmdahl, R. ( 2005 ). The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans . Eur J Immunol, 35, 357-366 .
40. Rudd, P.M. ( 2001 ). Glycosylation and the immune system . Science, 291, 2370-2376 .
41. Van Dyken, S.J., Locksley, R.M. ( 2007 ). Altered self-N-glycans trigger innate-mediated autoimmunity . Immunol Cell Biol, 85, 527-574 .
42. Chung, C.H., Mirakhur, B., Chan, E., Le, Q-T., Berlin, J., Morse, M., Murphy, B.A., Satinover, S.M., Hosen, J., Mauro, D., Slebos, R.J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D.J., Platts-Mills, T.A.E. ( 2008 ). Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1,3-galactose . N Engl J Med, 358 ( 11 ), 1109-1117 .
43. Armstrong, J.K., Hempel, G., Koling, S., Chan, L.S., Fisher, T., Meiselman, J.H., Garratty, G. ( 2007 ). Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients . Cancer, 110, 103-111 .
44. Brennan, F.R., Morton, L.D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Muller, P.Y., Frings, W., Sims, J. ( 2010 ). Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies . MAbs, 2 ( 3 ), 233-255 .
45. Niebecker, R., Kloft, C. ( 2010 ). Safety of therapeutic monoclonal antibodies . Curr Drug Saf, Jul 2 [Epub ahead of print].
46. Descotes, J. ( 2009 ). Immunotoxicity of monoclonal antibodies . MAbs, 1 ( 2 ), 104-111 .
47. Herzyk, D.J. ( 2003 ). The immunogenicity of therapeutic cytokines . Cur Op Mol Ther, 5 ( 2 ), 176-171 .
48. Wadhwa, M., Skog, A.-L. H., Bird, C., Ragnhammar, P., Lilljefors, M., Gaines-Das, R., Mellstredt, H., Thorpe, R. ( 1999 ). Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF . Clin Cancer Res, 5, 1353-1361 .
49. Thirumangalathu, R., Krishnan, S., Ricci, M.S., Brems, D.N., Randolph, T.W., Carpenter, J.F. ( 2009 ). Silicone oil-and agitation-induced aggregation of a monoclonal antibody in aqueous solution . J Pharm Sci, 98 ( 9 ), 3176-3181 .
50. Chi, E.Y., Weickmann, J., Carpenter, J.F., Manning, M.C., Randolph, T.W. ( 2005 ). Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation . J Pharm Sci, 94 ( 2 ), 256-274 .
51. Tyagi, A.K., Randolph, T.W., Dong, A., Maloney, K.M., Hitscherich, C. Jr, Carpenter, J.F. ( 2009 ). IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles . J Pharm Sci, 98 ( 1 ), 94-104 .
52. Jiang, Y., Nashed-Samuel, Y., Li, C., Liu, W., Pollastrini, J., Mallard, D., Wen, A.Z., Fujimori, K., Pallitto, M., Donahue, L., Chu, G., Torraca, G., Vance, A., Mire-Sluis, T., Freund, E., Davis, J., Narhi, L. ( 2009 ). Tungsten-induced protein aggregation: solution behavior . J Pharm Sci, 98, 4695-4710 .
53. Richard, J., Prang, N. ( 2010 ). The formulation and immunogenicity of therapeutic proteins: product quality as a key factor . IDrugs, 13 ( 8 ), 550-558 .
54. Rathore, N. ( 2008 ). Current perspectives on stability of protein drug products during formulation, fill and finish operations . Biotechnol Prog, 24, 504-514 .
55. Hochuli, E. ( 1997 ). Interferon immunogenicity: technical evaluation of interferon-a2a . J Interferon Cytokine Res, 17 ( Suppl. 1 ), S15-S21 .
56. Ryff, J.C. ( 1997 ). Clinical investigation of the immunogenicity of interferon-a2a . J Interferon Cytokine Res, 17 ( Suppl. 1 ), S29-S33 .
57. Sharma, B. ( 2007 ). Immunogenicity of therapeutic proteins. Part 2. Impact of container closure . Biotech Adv, 25, 318-324 .
58. Rosenberg, A.S., Worobec, A.S. ( 2004 ). A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 2. Considering host-specific and product-specific factors impacting immunogenicity . BioPharm Int, 1, 34-40 .
59. Ryan, M.H., Heavner, G.A., Brigham-Burke, M., McMahon, F., Shanahan, M.F., Gunturi, S.R., Sharma, B., Farrell, F.X. ( 2006 ). An in vitro model to assess factors that may stimulate the generation of an immune reaction to erythropoietin . Int Immunopharmacol, 6, 647-655 .
60. Schmidt, M., Raghavan, B., Muller, V., Vogl, T., Fejer, G., Tchaptchet, S., Keck, S., Kalis, C., Nielsen, P.J., Galanos, C., Roth, J., Skerra, A., Martin, S.F., Freudenberg, M.A., Goebeler, M. ( 2010 ). Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel . Nature Immunol 11, 814-819 [Epub ahead of print].
61. Kroon, D.J., Baldwin-Ferro, A., Lasan, P. ( 1992 ). Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping . Pharm Res, 9, 1386-1393 .
62. Gregory, R., Edwards, S., Yateman, N.A. ( 1991 ). Demonstration of insulin transformation products in insulin vials by high-performance liquid chromatography . Diabetes Care, 14, 42-48 .
63. Barbbosa, M.D., Vielmetter, J., Chu, S., Smith, D.D., Jacinto, J. ( 2006 ). Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity . Clin Immunol, 118, 42-50 .
64. Schernthaner, G., Morkenstein, M., Fink, M., Mayr, W.R., Menzel, J., Schober, E. ( 1983 ). Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals . Diabetes Care, 6 ( Suppl. 1 ), 43-48 .
65. Fakharzadeh, S.S., Kazazian, H.H. Jr . ( 2000 ). Correlation between Factor VIII genotype and inhibitor development in hemophilia A . Sem Thromb Hem, 26 ( 2 ), 167-171 .
66. Kishnani, P.S., Goldenberg, P.C., DeArmey, S.L., Heller, J., Benjamin, D., Young, S., Bali, D., Smith, S.A., Li, J.S., Mandel, H., Koeberl, D., Rosenberg, A., Chen, Y-T. ( 2010 ). Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants . Mol Genet Metab, 99, 26-33 .
67. Junzhi, L., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., Kutter, D. ( 2001 ). Thrombocytopenia caused by the development of antibodies to thrombopoietin . Blood, 98, 3241-3248 .
68. Steis, R.G., Smith, J.W. 2d, Urba, W.J., Clark, J.W., Itri, L.M., Evans, L.M., Schoenberger, C., Longo, D.L., et al. ( 1988 ). Resistance to recombinant interferon-alpha-2a in hairy cell leukemia associated with neutralizing anti-interferon-antibodies . N Engl J Med, 318, 1409 .
69. Maini, R.N., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Davis, D., Macfarlane, J.D., et al. ( 1998 ). Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis . Arthritis Rheum, 41, 1552-1563 .
70. Baert, F., Noman, M., Vermeire, S., Van Assche, G., D'Haens, G., Carbonez, A., et al. ( 2003 ). Influence of immunogenicity on the long-term efficacy of infliximab in Crohn ' s disease . N Engl J Med, 348, 601-608 .
71. Pozzilli, C., Antonini, G., Bagnato, F., et al. ( 2002 ). Monthly corticosteroids decrease neutralizing antibodies to IFNb-1b: a randomized trial in multiple sclerosis . J Neurol, 249, 50-56 .
72. Antonelli, G., Giannelli, G., Currenti, M., Simeoni, E., Del Vecchio, S., Maggi, F., Pistello, M., Roffi, L., Pastore, G., Chemello, L., Dianzani, F. ( 1996 ). Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-a 2 therapy . Clin Exp Immunol, 104, 384-387 .
73. Giovannoni, G. ( 2003 ). Strategies to treat and prevent the development of neutralizing anti-interferon-b antibodies . Neurology, 61 ( Suppl. 5 ), S13-17 .
74. Bertolotto, A., Malucchi, S., Sala, A., et al. ( 2002 ). Differential effects of three interferon betas on neutralizing antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory . J Neurol Neurosurg Psychiatry, 73, 148-153 .
75. Carpenter, J.F., Randolph, T.W., Jiskoot, W., Crommelin, D.J., Middaugh, C.R., Winter, G., Fan, Y.X., Kirshner, S., Verthelyi, D., Kozlowski, S., Clouse, K.A., Swann, P.G., Rosenberg, A., Cherney, B. ( 2009 ). Overlooking subvisible particles in therapeutic proteins products: gaps that may compromise product quality . J Pharm Sci, 98 ( 4 ), 1201-1205 .
76. Sharma, B. ( 2008 ). Immunogenicity of therapeutic proteins. Part 3. Impact of manufacturing changes . Biotech Adv, 25, 325-331 .
77. Steis, R.G., Smith, J.W. II, Urba, W.J., Venzon, D.J., Longo, D.L., Barney, R., Evans, L.M., Itri, L.M., Ewel, C.H. ( 1991 ). Loss of interferon antibodies during prolonged continuous interferon-a2a therapy in Hairy Cell Leukemia . Blood, 77, 792-798 .
78. Kakavanos, R., Turner, C.T., Hopwood, J.J., Kakkis, E.D., Brooks, D.A. ( 2003 ). Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I . Lancet, 361, 1608-1613 .
79. Pirazzoli, P., Cacciari, E., Mandini, M., Cicognani, A., Zucchini, S., Sganga, T., Capelli, M. . ( 1995 ). Follow-up of antibodies to growth hormone in 210 growth hormone-deficient children treated with different commercial preparations . Acta Paediatr, 84, 1233-1236 .
80. Underwood, L.E., Voina, S.J., Van Wyk, J.J. ( 1974 ). Restoration of growth by growth hormone (Roos) in hypopituitary dwarfs immunized by other hGH preparations: clinical and immunological studies . J Clin Endocrinol Metab, 38, 288-297 .
81. Herndon, R.M., Rudick, R.A., Munschauer, F.E. 3rd, Mass, M.K., Salazar, A.M., Coats, M.E., Labutta, R., Richert, J.R., Cohan, S.L., Genain, C., Goodkin, D., Toal, M., Riester, K. ( 2005 ). Eight-year immunogenicity and safety of interferon beta-1a-Avonex ® treatment in patients with multiple sclerosis . Mult cler, 11, 409.
82. Gneiss, C., Koudouovoh-Tripp, P.M., Popele, S., Gotwald, T., Ehling, R., Lutterotti, A., Aichner, F., Ladurner, G., Eggers, C., Schautzer, F., Kunz, B., Millonig, A., Aspeck, E., Reindl, M., Berger, T., Fazekas, F., Deisenhammer, F. ( 2009 ). Influence of interferon-beta therapy switching on neutralizing antibody titers: results from the Austrian Switch Study . Mult Scler, 15 ( 12 ), 1481-1488 .
83. Lallemand, C., Meritet, J.-.F., Erickson, R., Grossberg, S.E., Roullet, E., Lyon-Caen, O., Lebon, P., Tovey, M.G. ( 2008 ). Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene . J Interferon Cytokine Res, 28, 393-404 .
84. Brady, R.O., Murray, G.J., Oliver, K.L., Leitman, S.F., Sneller, M.C., Fleisher, T.A., Barton, N.W., and collaborators . ( 1997 ). Management of neutralizing antibody to ceredase in a patient with type 3 Gaucher disease . Pediatrics, 100, E11 .
85. Berntorp, E., Shapiro, A., Astermark, J., Blanchette, V.S., Collins, P.W., Dimichele, D., Escuriola, C., Hay, C.R., Hoots, W.K., Leissinger, C.A., Negrier, C., Oldenburg, J., Peerlinck, K., Reding, M.T., Hart, C. ( 2006 ). Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference . Haemophilia, 12 ( Suppl. 6 ), 1-7 .